LSA
CRVS icon

Leonteq Securities AG’s Corvus Pharmaceuticals CRVS Stock Holding History

Leonteq Securities AG’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$64.4K – 1283
2025
Q1 		$64.4K Buy
+20,000
New +$94.2K ﹤0.01% 798
2022
Q4 		– Sell
-10,000
Closed -$8.19K – 1307
2022
Q3 		$8.19K Buy
10,000
+2,000
+25% +$1.91K ﹤0.01% 1078
2022
Q2 		$7.92K Sell
8,000
-7,000
-47% -$8.59K ﹤0.01% 1116
2022
Q1 		$24.6K Buy
15,000
+14,000
+1,400% +$25.6K ﹤0.01% 977
2021
Q4 		$2.41K Buy
+1,000
New +$3.88K ﹤0.01% 1212

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Leonteq Securities AG's CRVS Position: Q2 2025 in Review

Leonteq Securities AG sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 20,000 shares — an estimated $64.4K sold.

Leonteq Securities AG first reported a position in CRVS in Q4 2021 and held it in 5 quarters. The position peaked at $64.4K in Q1 2025. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

  • Leonteq Securities AG reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Leonteq Securities AG sold 20,000 Corvus Pharmaceuticals shares in Q2 2025, an estimated $64.4K.
  • Leonteq Securities AG first reported a position in Corvus Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Leonteq Securities AG's Corvus Pharmaceuticals position peaked at $64.4K in Q1 2025.
  • 92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on Leonteq Securities AG's 13F filing for Q2 2025, filed 17 Feb 2026.